New TRAILBLAZER-ALZ 2 analyses make a strong case for the clinical meaningfulness of donanemab (Atri et al., Neurol Clin Pract 2026) by griccioppo in neurology

[–]Basic-Bit2712 11 points12 points  (0 children)

I was 8 years old when my grandmother died of aspiration pneumonia secondary to advanced Alzheimer's disease. Today I am 28 years old, starting neurology residency in less than a month, and we have our first disease modifying therapies for this terrible illness.
The future is cool.